| Study period | |||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Screening | Baseline | Home-based intervention | Short-term follow-up | Long-term follow-up | ||||||||||
Visits (weeks) | W-1 | W0 | W1 | W2 | W3 | W4 | W5 | W6 | W7 | W8 | W9 | W10 | W34 | |
Informed consent | X | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | |
Eligibility screen | X | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | |
Randomization | X | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | |
Neuropsychological assessment 1 | Cognitive complaint questionnaire | X | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â |
BCcogSEP | X | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | |
VAPS | X | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | |
Multiple errands test | X | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | |
Neuropsychological assessment 2 | MUSIQOL | Â | X | Â | Â | Â | Â | Â | Â | Â | Â | Â | X | X |
SEI | Â | X | Â | Â | Â | Â | Â | Â | Â | Â | Â | X | X | |
MADRS | Â | X | Â | Â | Â | Â | Â | Â | Â | Â | Â | X | X | |
HAMA | Â | X | Â | Â | Â | Â | Â | Â | Â | Â | Â | X | X | |
BICAMS = SDMT, CVLT-II, BVMT-R |  | X |  |  |  |  |  |  |  |  |  | X | X | |
MCQ-30 | Â | X | Â | Â | Â | Â | Â | Â | Â | Â | Â | X | X | |
EMIF-SEP | Â | X | Â | Â | Â | Â | Â | Â | Â | Â | Â | X | X | |
PSQI | Â | X | Â | Â | Â | Â | Â | Â | Â | Â | Â | X | X | |
Active control group | At-home set-up | Â | Â | X | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â |
Phone follow-up | Â | Â | Â | X | X | X | Â | X | X | X | X | Â | Â | |
At-home follow-up | Â | Â | Â | Â | Â | Â | X | Â | Â | Â | Â | Â | Â | |
Experimental group with CR intervention | CR intervention | Â | Â | Â | X | X | X | X | X | X | X | X | Â | Â |
At-home set-up | Â | Â | X | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | |
Phone follow-up | Â | Â | Â | X | X | X | Â | X | X | X | X | Â | Â | |
At-home follow-up | Â | Â | Â | Â | Â | Â | X | Â | Â | Â | Â | Â | Â |